CCR9 and non-small cell lung carcinoma: They boost the host immunity during NSCLC immunotherapy by increasing Th1 lymphocytes and in IL‐12‐dependent manner, boosting the amount of IFN‐γ, and attracting CCR9 + CXCR3 + CD4 + T cells towards cancer cells.